unknown
Stage
About
Versartis was a biopharmaceutical company developing long-acting growth hormone therapies, including somavaratan (VRS-317), for the treatment of growth hormone deficiency.
Explore Versartis's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.